AGP
GILD icon

Aspire Growth Partners’s Gilead Sciences GILD Stock Holding History

Aspire Growth Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
1,959
+12
+0.6% +$1.58K 0.14% 113
2026
Q1 		$271K Buy
1,947
+12
+0.6% +$1.68K 0.19% 99
2025
Q4 		$238K Buy
1,935
+12
+0.6% +$1.46K 0.17% 110
2025
Q3 		$213K Buy
1,923
+13
+0.7% +$1.48K 0.16% 113
2025
Q2 		$212K Buy
+1,910
New +$203K 0.17% 111

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aspire Growth Partners's GILD Position: Q2 2026 in Review

Aspire Growth Partners increased its Gilead Sciences (GILD) stake by 0.62% in Q2 2026, buying an estimated $1.58K and bringing the position to 1,959 shares worth $248K. The position accounts for 0.14% of the portfolio, ranked #113.

Aspire Growth Partners first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $271K in Q1 2026. 2,279 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Aspire Growth Partners held 1,959 shares of Gilead Sciences worth $248K as of Q2 2026.
  • Aspire Growth Partners bought 12 Gilead Sciences shares in Q2 2026, an estimated $1.58K.
  • Gilead Sciences made up 0.14% of Aspire Growth Partners's portfolio in Q2 2026, its #113 holding.
  • Aspire Growth Partners first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Aspire Growth Partners's Gilead Sciences position peaked at $271K in Q1 2026.
  • 2,279 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Aspire Growth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.